INTRODUCTION: This study designed to verify the antiangiogenic activity of ferulic acid (FA) and its potency to inhibit COX-2 and VEGF expression on CAM model. Moreover besides, we verified its mechanism of action by docking the molecule on COX-2, tyrosine kinase and VEGF-2 proteins in silico METHODS: Anti-angiogenesis assay of FA at the doses of 30, 60 and 90 μg were performed using CAM of chicken eggs with nine-day old which were stimulated by 60 ng basic fibroblast growth factor (b-FGF). Celecoxib 60 μg was used as reference drug. The inhibitory activity on VEGF and COX-2 expressions were conducted by immunohistochemistry assay (IHC). Molecular docking of FA were accomplished by Molegro Virtual Docker program ver. 5.5. on COX-2 enzyme (PDB ID 1CX2), tyrosine kinase receptor (PDB ID 1XKK) and VEGF-2 receptor (PDB ID 4ASD). RESULTS: FA at doses 30, 60, 90 μg significantly prevented angiogenesis on CAM model (p<0.05), which were represented as inhibitory activities against endothelial cell of blood vessels (42.6-70.7%) and neovascularization (43.0-86.6%). Inhibitory activities of FA against VEGF expression were stronger than its action on COX-2 expression. Molecular docking on VEGF-2 receptor result in RS value of FA was -73,844 kcal/mol, and celecoxib was -94.557 kcal/mol. RS value on tyrosine kinase of FA was -84.954 kcal/mol, while celecoxib was -93.163 kcal/mol. Docking on COX-2 receptor denoted RS value of FA was -73,416 kcal/mol, while celecoxib was -118,107 kcal/mol. DISCUSSION AND CONCLUSION: Reduction of VEGF-2 & COX-2 expression due to treatment with FA at dose range 30-90 μg seem to be related to angiogenesis inhibition, which is presented by two parameters, namely inhibition of neovascularization and endothelial cell growth in blood vessels It was concluded that FA is promising anti-angiogenic therapeutic agent especially at early stage, and this activity can be resulted from inhibitory action on COX-2 and VEGF-2 proteins.
Introduction
The progression of cancer cells depends heavily on angiogenesis, the formation of new blood vessels which supply oxygen and food required for tumor's cell proliferation and metastases progression 1, 2 . The development of cancer cells is induced by angiogenesis which is activated by some growth factors such as vascular endothelial growth factor receptor (VEGFR). Two important growth factor receptors which influence angiogenesis are tyrosine kinase receptor (TKR) and VEGFR-2 1, 3 .
The vascular endothelial growth factor (VEGF) signaling pathway is a strategic target for the angiogenesis inhibitors 4, 5 . But, there are some clinical problems of u n c o r r e c t e d p r o o f angiogenesis inhibitors in patients (i.e. thromboembolic disorders, intracranial hemorrhagia, and bowel perforation) 6 . Other problems are the occurrence of toxicities such as bleeding, fatigue, hypertension, perforation in gastrointestinal tract 7, 8 . Therefore, the study of new antiangiogenic substance which is relatively safe in their pharmaceutical dosage form is one of some important steps in cancer treatment.
Ferulic acid (FA), [3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid] (Figure 1 ) is a phenolic acid compound, which has antioxidant 9, 10 , and cytotoxic activities in many cancer cell lines 11, 12 . Wang et al. (2016) reported that FA could inhibit proliferation and induced apoptosis of osteosarcoma cell via PI3K/Akt pathway 13 . FA also had antiinflammatory activity and inhibited cyclooxygenase-2(COX-2) enzyme 14 which were related to angiogenesis 2, 15 . Koki et al. (2003) reported that COX-2 expression increased during the tumorigenesis process and the intensity of its expression was in line with the degree of carcinogenesis 16 . Wu et al. (2006) reported that biosynthesis result of prostaglandin which was catalyzed by COX-2, could stimulate the vascular endothelial growth factor (VEGF) expression in tumor cells and acted as a positivefeedback loop between tumor cells and endothelial cells 17 .
In an effort to improve FA as a drug candidate for cancer chemoprevention, we study its antiangiogenic activity and inhibitory activity against COX-2 and VEGF expression on the chicken egg chorioallantoic membranes (CAM) model. The CAMs assay is a robust and applicable technique to assess a potential drug candidate. The assay has been commonly used to study angiogenesis and tumor invasion in various type of cancer 18, 19 . To verify FA's mechanism in inhibition of angiogenesis, we conducted molecular docking on COX-2 enzyme, tyrosine kinase,and VEGF-2 receptors.
Material and Methods

Materials
Commercially available materials were used as obtained. Ferulic acid, Tris-HCl and basic-Fibroblast Growth Factor (bFGF) were purchased from Sigma-Aldrich (St Louis, MO, USA). The chicken eggs were collected from PUSVETMA Surabaya, Indonesia.
CAM assay
Twenty-fiveof nine-day-old chicken eggs were incubated at 37ºC (60-70% humidity) for one day. All of the treatment groups of CAMs were induced by bFGF at a concentration of 1 ng/μl, in Tris-HCl solution of pH 7.5. The eggs were spread into five u n c o r r e c t e d p r o o f groups; each group consists of six eggs. Three groups were treated with FA at dosages of 30, 60, 90g; the positive control group was treated with celecoxib 60gand one group without treatment which was set as the negative control. The egg was perforated to make a hole of 1 cm 2 in diameter to remove the air. The sterile Whatman filter-paper disks of 5-mm in diameter with tested compound and bFGF or bFGF alonewere dropped into the hole and then were impregnated onto CAM of each embryo. The hole was covered and restored to incubation at 37ºC (60% humidity) for 72 hours. After incubation, the upper eggshell was opened and the presence of neovascularization from the main blood vessels onto the paper disks were counted. In addition, we also collected the blood vessels of CAM in the formalin buffer and carried out microscopic observations of the histopathologic slide of the CAMusing Hematoxylin and Eosin (HE) staining. To confirm the antiangiogenic activity, this CAM assay was achieved with certain alteration as explained before 18, 20 . The growth of the endothelial cell in the neovascular capillaries wasexposed in CAM cross-sections by an inverted phase contrast microscope, Nikon H600L. The number of endothelial cells at five graphical fields were calculated, whereas each slidewas observed at 400x amplification and compared with positive or negative control groups for the following analysis.
Antibody:
Rabbit polyclonal anti-humanCOX-2 and VEGF antibody were obtained from Thermo 
Immunohistochemical assay
The slides for immunohistochemical assay were prepared at Laboratory of Anatomical Pathology, Dr. Sardjito Hospital, Yogyakarta, Indonesia. Paraffin blocks of the CAM containing blood vessels were cut in 3-4 μm thick and placed on the poly-lysine slide, then they were incubated overnight at 45ºC. The next step of VEGF or COX-2 staining for the immunohistochemical assay was carried out as reported in previous research 18, 19 . In this study, we used Hematoxylin Mayer as counterstaining. The Tris-EDTA solution at pH 9 was used in the retrieval step of VEGF staining for 15-20 min, whereas pH 6 citrate buffer was used for retrieval COX-2 staining for 15-20 min. The slides divided into six groups. One group consist of slides of CAM expressing COX-2 protein which was used as positive control, three groups contain slides of FA at doses of 30, 60 and 90 g, one group were slides of celecoxib at a dose of 60g which was u n c o r r e c t e d p r o o f used as the reference drug, and one group was used as a negative control group.
The microscopic observation of VEGF expression and COX-2 expression were continued by counting the visible brown cells at five fields for a minimum of 100 cells.
Statistical Analysis
The obtained data were determined to an analysis by ANOVA, one-way Fisher test (F) at 95% level of confidence. If there was a significant variance among each group, the analysis was continued by Duncan multiple range test. Statistical significant was stated if P<0.05. All statistical analyses were presented using IBM SPSS Statistic 21
program.
Molecular Docking Equipment
Hardware: Laptop ASUS AMD A8 Vision with CPU @1.9 GHz, 4GB of RAM Software: CS ChemBio Draw Ultra version 12.00 (Cambridge Soft) was utilized to create the three-dimensional structure (3D) of FA which was then subjected to energy minimization by MMFF94 method and the 3D structure was saved as SYBYLMol2 format (*.Mol2). Program Molegro Virtual Docker (MVD) version 5.5 (CLC Bio) was employed as a docking program in this research. The 3D structure of COX-2, TKR, and VEGF-2 proteins were downloaded from website (http://www.rcsb.org/pdb/home /home.do).
In silico assay
The 3D structure of three proteins which were obtained from a protein data bank were used for further visual inspection (Figure 5-7) . The validation of the docking result was performed by redocking the reference ligand into the same cavity in each protein. Redocking result was accepted if root means square value (RMSD) < 2.0 Aº.
Results and Discussion
Antiangiogenic Activity of FA
The anti-angiogenesis assay is performed on the CAM of the embryonated chicken egg because the membrane is the site of very high vascularization and easily observable in line with the process of chicken embryo growth 18, 21 . The CAM is a fusion of chorion and allantois of chicken egg membrane which is formed after 4 days Table 1 . 
vessels between FA at dose 90g and celecoxib at dose 60g (P<0.05).As a reference drug, celecoxib 60μg providing 83% of new blood vessel growth inhibition on the CAM model.
FA inhibited VEGF and COX-2 expression
The microscopic image of VEGF expression in the endothelial cell of the new blood vessels belongs to the positive control group is dominated by the presence of brown color. It is very contrast when compared with an image from the negative control group, it displays the dominant blue color in the endothelial cell cytoplasm. The brown color on the cytoplasm which indicates VEGF expression of the endothelial cell treated by FA decreases with increasing dosage of the substance from 30μg to 90μg.
The microscopic observation results of VEGF expression in each treatment group presented in Figure 3 .
The microscopic observation results of COX-2 expression in each treatment group presented in Figure 4 . All data of the treatment group were presented in Table   2 . and analyzed statistically by SPSS 21.0 version for Windows software.
Analysis of percentage inhibition of VEGF expression by FA, using the Normality
One-sample Kolmogorov-Smirnov test showed probability or p = 0.398, whereas percentage inhibition of COX-2 expression with the Normality One-sample Kolmogorov-Smirnov test showed probability or p=0.458. This means the data is normally distributed because of greater than 0.05 (p>0.05). Based on the data in Table 2 , it is known that giving 30-90 μg FA decreases VEGF expression in CAM significantly. Reduced of VEGF expression due to treatment with FA at doses 30-90μg is in line with angiogenesis inhibition, which appears in two parameters, namely neovascularization or resistance to endothelial cell growth of blood vessels on the chick embryo chorioallantoic membrane.
u n c o r r e c t e d p r o o f
The main VEGF receptor on endothelial cells is VEGFR2, which influenced during development and adult cells. The VEGFR2 signaling is better recognized than the other VEGF receptors. The vascular permeability is essentialin vivo consequence of VEGFR2 activation. Several small-molecular-weight inhibitors of VEGFR2 kinase activity are employed clinically to block pathological angiogenesis in cancer 13 .
In vitro experiments of capillary endothelial cells showed that VEGF is a powerful stimulator against the occurrence of angiogenesis. This is due to its presence as a growth factor triggering the proliferation and migration of endothelial cells, even the formation of tube formation in a series of capillary vessels 28 . Inhibition of VEGF can occur in several options, the first is inhibition at the VEGF receptor , has been reported to inhibit the growth of prostate, gastric, lung, and breast cancer 24, 25 . The induction of b-FGF as proangiogenic compounds will lead to an inflammation associated with the COX-2 activity 26, 27 . As well as celecoxib, FA also inhibited COX-2 enzyme 14, 28 , so it could obstruct the b-FGF activity as a pro-angiogenic compound.
Based on the inhibitory mechanism of angiogenesis through the inhibition of VEGF expression conducted by other researchers in several studies, it is possible that FA inhibits VEGF receptor (VEGFR-2) through its inhibitory activity on tyrosine kinase and COX-2. This assumption is studied and proven through in silico docking on COX-2, TKR, and VEGFR-2.
Docking Study
The best-docked pose of FA, celecoxib, BAX ligands in the binding site of VEGFR-2 and the interactions between functional groups of FA and Celecoxib with amino acid residues in two dimensional (2D) structure are shown in Figure 5 . The docking scores (RS value), the type of bonding interactions with VEGFR-2 and amino acids involved in their interactions were listed in Table 3 .
The best-docked pose of FA, celecoxib, native ligand in the binding site of Tyrosine kinase and their interactions with amino acid residues in two dimensional (2D) structure are shown in Figure 6 . The RS value, the type of interactions and amino acids involved in the interaction between ligand and tyrosine kinase receptor (TKR) were listed in Table4.
The ligand of PDB ID 1XKK contains a benzylic group (Ar-C-) which acts as a pharmacophore in the ligand-receptor interaction complex. The FA compound contains a similar group which is also expected as a pharmacophore. Celecoxib that produces lower RS value than FA (Table 3) and their interactions with amino acid residues in two dimensional (2D) structure are shown in Figure 7 . The RS value, the type of bonding interactions with COX-2 and amino acids involved in their interactions were listed in Table 5 . 
Conclusions
Ferulic acid (at dosage of 30-90g) is a promising anti-angiogenic therapeutic agent, especially in an early stage of angiogenesis process. It prevents pro-angiogenic growth factor which leads to inflammation (i.e. b-FGF), the activity of MMP and development of branching of blood vessels. This activity result from inhibitory action on COX-2 and VEGF-2 proteins.
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